Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin

Clinical Pharmacology and Therapeutics

Volumn 73, Issue 3, 2003, Pages 159-169

  Hamzeh, Fayez M ^a   Benson, Constance ^b   Gerber, John ^b   Currier, Judith ^b   McCrea, Jackie ^b   Deutsch, Paul ^b   Ruan, Ping ^b   Wu, Hulin ^b   Lee, Jin ^b   Flexner, Charles ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

25 DEACETYLRIFABUTINE; DRUG METABOLITE; INDINAVIR; RIFABUTIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERKALEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; VERTIGO; VOMITING;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE; MIDDLE AGED; RIFABUTIN;

EID: 0037374606     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2003.3     Document Type: Article

References (47)

1. Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000;133:35-9.
2. Griffith DE. Risk-benefit assessment of therapies for Mycobacterium avium complex infections. Drug Saf 1999;21:137-52.
3. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997;41:654-60.
4. Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Saf 1999;20:147-69.
5. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001;344:984-96.
6. Sahai J, Gallicano K, Swick L, Tailor S, Garber G, Seguin I, et al. Reduced plasma concentrations of anti-tuberculosis drugs in patients with HIV infection. Ann Intern Med 1997;127:289-93.
7. Scott LJ, Perry CM. Delavirdine: a review of its use in HIV infection. Drugs 2000;60:1411-44.
8. Slain D, Pakyz A, Israel DS, Monroe S, Polk RE. Variability in activity of hepatic CYP3A4 in patients infected with HIV. Pharmacotherapy 2000;20:898-907.
9. Barditch-Crovo P. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clin Pharmacol Ther 1999;65:428-38.
10. Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993;25:450-82.
11. Grange JM, Winstanley PA, Davies PD. Clinically significant drug interactions with antituberculosis agents. Drug Saf 1994;11:242-51.
12. Jamis-Dow CA. Rifampin and rifabutin and their metabolism by human liver esterases. Xenobiotica 1997;27:1015-24.
13. Oesch F, Arand M, Benedetti MS, Castelli MG, Dostert P. Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver. J Antimicrob Chemother 1996;37:1111-9.
14. Reinach B, de Sousa G, Dostert P, Ings R, Gugenheim J, Rahmani R. Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes. Chem Biol Interact 1999;121:37-48.
15. Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. Clin Infect Dis 1996;22(Suppl 1):S15-21.
16. Dhillon J. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages. Am Rev Respir Dis 1992;145:212-4.
17. Grassi C, Peona V. New drugs for tuberculosis. Eur Respir J Suppl 1995;20:714s-8s.
18. Kunin CM. Antimicrobial activity of rifabutin. Clin Infect Dis 1996;22(Suppl 1):S3-13.
19. Gordin F, Masur H. Prophylaxis of Mycobacterium avium complex bacteremia in patients with AIDS. Clin Infect Dis 1994;18(Suppl 3):S223-6.
20. Moore RD, Chaisson RE. Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS. AIDS 1995;9:1337-42.
21. Singer J, Thorne A, Khorasheh S, Raboud JM, Wu AW, Salit I, et al. Symptomatic and health status outcomes in the Canadian randomized MAC treatment trial (CTN010). Canadian HIV Trials Network Protocol 010 Study Group. Int J STD AIDS 2000;11:212-9.
22. Cocchiara G, Strolin BM, Vicario GP, Ballabio M, Gioia B, Vioglio S, et al. Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers. Xenobiotica 1989;19:769-80.
23. Trapnell CB, Jamis-Dow C, Klecker RW, Collins JM. Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole. Antimicrob Agents Chemother 1997;41:924-6.
24. Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998;87:803-7.
25. Flexner C. Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. Annu Rev Pharmacol Toxicol 2000;40:649-74.
26. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47(RR-20):1-58.
27. Chevalley GF, Kaiser L, Bouchenaki N, Baglivo E, Kress O. Uveitis associated with rifabutin treatment. Apropos of 3 patients. Klin Monatsbl Augenheilkd 1995;206:388-90.
28. Gariano RF, Cooney EL. Uveitis following administration of the protease inhibitor indinavir to a patient with AIDS. Clin Infect Dis 1997;24:529-31.
29. Fournier S, Deplus S, Janier M, Poinsignon Y, Decazes JM, Modai J. Anterior uveitis in HIV-infected patients. 3 cases in patients treated with an antiprotease. Presse Med 1998;27:844-8.
30. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998;35:275-91.
31. Lin JH. Human immunodeficiency virus protease inhibitors. From drug design to clinical studies. Adv Drug Deliv Rev 1997;27:215-33.
32. Burger DM, Hoetelmans RM, Hugen PW, Mulder JW, Meenhorst PL, Koopmans PP, et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther 1998;3:215-20.
33. Woolf E, Au T, Haddix H, Matuszewski B. Determination of L-735 524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching. J Chromatogr A 1995;692:45-52.
34. Lewis RC, Hatfield NZ, Narang PK. A sensitive method for quantitation of rifabutin and its desacetyl metabolite in human biological fluids by high-performance liquid chromatography (HPLC). Pharm Res 1991;8:1434-40.
35. Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications. 2nd ed. Stockholm (Sweden): Apotekarsocieteten, Swedish Pharmaceutical Press; 1997.
36. Acosta EP, Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 2000;30(Suppl 2):S151-9.
37. Hogg RS, Yip B, Kully C, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected patients after initiation of triple-drug anti-retroviral regimens. CMAJ 1999;160:659-65.
38. Shafran SD, Singer J, Zarowny DP, Phillips P, Salit I, Walmsley SL, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N Engl J Med 1996;335:377-83.
39. Siegal FP, Eilbott D, Burger H, Gehan K, Davidson B, Kaell AT, et al. Dose-limiting toxicity of rifabutin in AIDS-related complex: syndrome of arthralgia/arthritis. AIDS 1990;4:433-41.
40. Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E, et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 1998;26:552-61.
41. Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 1996;24:307-14.
42. Chiba M, Nshime JA, Lin JH. In vitro metabolism of indinavir in the human fetal liver microsomes. Drug Metab Dispos 1997;25:1219-22.
43. Jarvis B, Faulds D. Nelfinavir. A review of its therapeutic efficacy in HIV infection. Drugs 1998;56:147-67.
44. Cato A, Cavanaugh J, Shi H, Hsu A, Leonard J, Granneman R. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther 1998;63:414-21.
45. Schaller UC, Michl G, Goebel FD, Klauss V. Acute hypopyon uveitis with rifabutin therapy of systemic Mycobacterium avium complex (MAC) infection in AIDS [in German]. Ophthalmologe 1999;96:267-9.
46. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001;2:105-13.
47. Casado JL, Moreno A, Sabido R, Marti-Belda P, Antela A, Dronda F, et al. A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response. HIV Clin Trials 2000;1:13-9.